Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1902 • ACR Convergence 2024
Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Merete Hetland² and Bente Glintborg³, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Clinical trials have provided robust evidence of the efficacy of ixekizumab, an IL-17 inhibitor, in improving the signs and symptoms of psoriatic arthritis (PsA)…
Abstract Number: 2315 • ACR Convergence 2024
Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
Theo WIRTH¹, Emmanuel Massy², Nathalie Lambert³, Isabelle Auger³, Nathalie Balandraud¹ and Florent Amatore⁴, ¹Department of Rheumatology, Sainte Marguerite Hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France, ²Department of Rheumatology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ³INSERM UMRs1097, Arthrites autoimmunes, Marseille, Marseille, France, ⁴Department of Dermatology, Nord hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, MARSEILLE 9EME, France
Background/Purpose: Psoriatic arthritis (PsA) can be challenging to diagnose due to the lack of specific biomarkers. Although a few teams have demonstrated the presence of…
Abstract Number: 2332 • ACR Convergence 2024
PsAID12 Thresholds Defining Disease Impact Severity in Psoriatic Arthritis Developed in an Observational Setting Showed Higher Sensitivity but Lower Specificity Than Those Developed in a Randomized Controlled Trial Setting
Clementina López Medina¹, Ana-Maria Orbai², Ennio Lubrano³, Laura Coates⁴, Uta Kiltz⁵, Ying Ying Leung⁶, PENELOPE PALOMINOS⁷, Juan Cañete⁸, Rossana Scrivo⁹, Andra Balanescu¹⁰, Emmanuelle Dernis¹¹, Sandra Meisalu¹², Adeline Ruyssen-Witrand¹³, MArtin Soubrier¹⁴, Sibel Aydin¹⁵, Lihi Eder¹⁶, Umut Kalyoncu¹⁷, Josef Smolen¹⁸, Maarten de Wit¹⁹ and Laure Gossec²⁰, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ⁴University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁶Singapore General Hospital, Singapore, Singapore, ⁷Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ⁸Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁹Sapienza Università di Roma, Rome, Italy, Roma, Italy, ¹⁰UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ¹¹CH LE MANS, LE MANS, Pays de la Loire, France, ¹²Physician, Tallinn, Estonia, ¹³Toulouse University Hospital, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵University of Ottawa - Ottawa, Ottawa, ON, Canada, ¹⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ¹⁷Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁸Medical University of Vienna, Vienna, Austria, ¹⁹Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ²⁰Sorbonne Université, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score (range 0-10) allows for the assessment of patient-important symptoms and life impact in PsA.…
Abstract Number: 2353 • ACR Convergence 2024
Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Toby Thomas⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Pharmaceuticals, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel MedSci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…
Abstract Number: 2585 • ACR Convergence 2024
Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Stefan Siebert¹, Mohamed Sharaf², Carlo Selmi³, Proton Rahman⁴, Mitsumasa Kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Minni Koivunen⁹, Frederic Lavie¹⁰, Ruben Queiro Silva¹¹, Frank Behrens¹², Ennio Lubrano¹³ and Laure Gossec¹⁴, ¹School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ³Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ⁴Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁶Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Data Sciences Staffing Solutions, IQVIA, Inc, Budapest, Hungary, ⁹Janssen Cilag Oy, Espoo, Finland, Espoo, Finland, ¹⁰Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹¹Rheumatology Division, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Oviedo, Spain, ¹²University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ¹³Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ¹⁴Sorbonne Université, Paris, France
Background/Purpose: PsA leads to significant patient-perceived burden of disease. Targeted drugs have demonstrated efficacy in randomised controlled trials including in aspects of patient-reported impact. However,…
Abstract Number: 0227 • ACR Convergence 2024
Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study
Julio Ramírez¹, Vicenç Torrente-Segarra², Andrea Cuervo³, Mireia Moreno⁴, Ana Belén Azuaga¹, Lourdes Mateo⁵, Beatriz Frade-Sosa⁶, Andrea Zacarias¹, Noemí Busquets Pérez⁷, Susana Holgado⁸, Paula Estrada-Alarcón⁹, Delia Reina¹⁰, Juan José De Agustín¹¹, Carme Moragues¹², María Bonet¹³, Sandra Farietta¹, Patricia Corzo¹, Andrés Ponce¹⁴, Virginia Ruiz Esquide¹, Lucia Alascio¹ and Juan Cañete¹⁵, and ECOCAT group, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³Hospital General Granollers, Granollers, Spain, ⁴Hospital Parc Taulí, Sabadell, Spain, ⁵Hospital Germans Trias i Pujol, Badalona, Spain, ⁶Hospital Clínic, Barcelona, Spain, ⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁸Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Hospital Moises Broggi, Barcelona, Spain, ¹¹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹²Hospital Bellvitge, Barcelona, Spain, ¹³Hospital Alt Penedés i Garraf, Barcelona, Spain, ¹⁴Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ¹⁵Hospital Clinic an IDIBAPS, Barcelona, Spain
Background/Purpose: The ultrasound (US) finding of proliferative synovitis (PS) in Rheumatoid Arthritis (RA), is associated with ACPA, erosions and changes in therapy [1]. However, no…
Abstract Number: 0588 • ACR Convergence 2024
Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Laura Coates¹, Carlo Selmi², Philip Mease³, Alexis Ogdie⁴, Francois Nantel⁵, Frederic Lavie⁶, Mohamed Sharaf⁷, Oyediran Adelakun⁸, Emmanouil Rampakakis⁹, Laura Pina Vegas¹⁰ and Lihi Eder¹¹, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Nantel MedSci Consult, Montreal, QC, Canada, ⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁷Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁸Janssen Research & Development, LLC, Titusville, NJ, ⁹McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…
Abstract Number: 0974 • ACR Convergence 2024
Number of Days Between Prior Low-dose Weekly Methotrexate Administration and S1-RBD Antibody Response in Adults with Immune Mediated Inflammatory Diseases Vaccinated Against COVID-19: Secondary Analysis of the Vaccine Response On-Off Methotrexate (VROOM) Study Data
Abhishek Abhishek¹, Nicholas Peckham² and Jonathan Cook², and the VROOM Study Author Group, ¹University of Nottingham, Nottingham, United Kingdom, ²Oxford University, Oxford, United Kingdom
Background/Purpose: Immunosuppression attenuates immune response to vaccination. A 2-week interruption in low-dose weekly methotrexate immediately after COVID-19 booster improved antibody response to vaccination. There is…
Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Bella Garg¹, John Antowan² and daniel Furst³, ¹Centinela Hospital Medical Center, Inglewood, CA, ²UCLA, Los Angeles, ³Pacific Arthritis Center, Inglewood
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
Abstract Number: 1467 • ACR Convergence 2024
Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
William Tillett¹, Simona Rednic², Kristi Mizelle³, Christopher Ritchlin⁴, Saakshi Khattri⁵, Linyu Shi⁶, Brenton Bialik⁶, Thomas Iyile⁷ and Arthur Kavanaugh⁸, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Department of Rheumatology, "Iuliu Hațieganu" University of Medicine and Pharmacy and County Emergency Hospital, Cluj-Napoca, Romania, ³Tidewater Physicians Multispecialty Group (TPMG) Rheumatology, Newport News, VA, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Mount Sinai Medical Center, New York, NY, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., hyattsville, MD, ⁸University of California San Diego, La Jolla, CA
Background/Purpose: The phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized double-blind clinical trials demonstrate that risankizumab (RZB) provides a high level of durable improvement in…
Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 2316 • ACR Convergence 2024
Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Pauline KRUG¹, angela De Sousa Leite², Frédéric Lecouvet¹, Maria Simona stoenoiu¹ and Adrien Nzeusseu Toukap³, ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires St-Luc, Brussels, Belgium, ³Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogenous chronic inflammatory condition. Recent publications highlight differences between men and women in disease manifestation and response to…
Abstract Number: 2333 • ACR Convergence 2024
Unveiling New Molecular Signatures in Psoriatic Arthritis Using Comprehensive Proteomic Analysis of Peripheral Mononuclear Cells
Eduardo Martin-Salazar¹, Iván Arias-de la Rosa², Laura Cuesta-López³, María Lourdes Ladehesa-Pineda⁴, Miriam Ruiz-Ponce³, Antonio Barranco³, Maria Angeles Puche-Larrubia⁵, Carlos Perez-Sanchez³, Yas Hanaee³, Pedro Ortiz-Buitrago³, Rosario Lopez Pedrera³, Alejandro Escudero-Contreras³, Eduardo Collantes-Estevez⁶, Clementina López Medina⁷ and Nuria Barbarroja³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordonba, Spain, ²Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁵Reina Sofía University Hospital, Cordoba, Spain, ⁶Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba 14012, Spain, ⁷Reina Sofia University Hospital, Cordoba, Spain
Background/Purpose: Diagnosing psoriatic arthritis (PsA) is challenging, underscoring the importance of discovering novel biomarkers through proteomics for early and accurate detection. Molecular clustering can elucidate…
Abstract Number: 2354 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Cynthia Vizcaya⁴, Reema Sutariya⁵, Wenhao Cao⁵ and Atul Singhal⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Southwest Arthritis Research Group, Mesquite, TX
Background/Purpose: To assess baseline demographics and clinical characteristics of patients with PsA that are most associated with achievement of clinical response to intravenous (IV) secukinumab…
Abstract Number: 2586 • ACR Convergence 2024
Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Maria Gabriella Raimondo¹, Hashem Mohammadian², Stefano Alivernini³, Simon Rauber¹, Filippo Fagni⁴, Giulia Corte⁵, Koray Tascilar², Maria Antonietta D´Agostino⁶, Georg Schett⁷, Arnd Kleyer⁸ and Andreas Ramming¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, Rome, Italy, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Charité - Universittsmedizin Berlin, Erlangen, Germany
Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.